- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02290990
Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS (DIMMISI)
A Randomized Controlled Trial on Integrated Imaginative Distention in MS Ans Insomnia: a Self Managed Tool to Cope With Fatigue, Stress and Insomnia
Imaginative Distention (ID) is proposed as supportive and integrative intervention to cope with fatigue, (principal end point), to cope with insomnia, stress perception and to improve QoL of pw MS, insomnia pw and health care personnel. ID is safe and it can be easily learned and practised without of any particular instrument and also feasible in disabled pw. This technique allows persons to experience the body as a source of well-being and not just fatigue, pain and disease. ID can become a self managed tool of empowerment to cope with MS, to reduce its negative impact on daily life and job performances. Adherence to pharmacological therapies could be improved using ID.
For pw MS ID could have specific and customizable rehabilitation implications to improve motor disability, as already seen in stroke patients. The principal end point of the trial is verify ID efficacy on fatigue and its specificity on pw MS at the end of the training. For this reason, ID efficacy will be tested in comparative terms too. Among all possible comparison populations, we selected: pw insomnia, which is stress related disease and health personnel, because at risk of stress. The control groups comparison permits to evaluate the specificity of ID on pw MS. The three groups are randomised to intervention or waiting list. The training is 8 weekly session long. Self administered questionnaire are filled by participants before and after the training, and 3-6 months later. The extent of change in outcome measure monitored in each exposed group vs. unexposed will allow to separate the non-disease specific effect of ID from the MS-specific effect. The difference in estimates will allow to determine the extent of the true effect of ID in pw MS. All outcome measure will be compared among all groups mentioned and over time. The study would identify also the most important outcome measures for MS patients questioning them in a focus group. This aspect is very important because could differs from which clinicians and researchers think about.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Milano, Italy, 20162
- Azienda Ospedaliera Ospedale Niguarda Ca' Granda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- any gender, ethnicity
- aged 18-65 years
- ability to understand Italian to be able to conduct the study
- adherence to the study by written informed consent
- absence of serious internal medicine and psychiatric comorbidities
Exclusion Criteria:
- under 18 and above 65 years
- lack of understanding Italian to conduct of the studies
- inability to provide informed consent
- presence of severe internal medicine and psychiatric comorbidities
Specific criteria for inclusion:
Pw MS:
- Diagnosis according to the criteria of Polman, 2011: relapsing remitting or progressive (primary and secondary)
- Or in no specific drug therapy for the disease and symptomatic
Pw insomnia:
- Diagnosis of psychophysiological insomnia according to DSM IV
- Or in no specific drug therapy for the disease and symptomatic
Healthy professionals:
- Healthy personnel operating within the Niguarda Hospital
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Multiple Sclerosis patients
Patients with MS
|
ID is an Imaginative relaxation technique which combines physical and mental relaxation.
ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning.
Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
|
|
EXPERIMENTAL: Insomnia patients
Patients with insomnia
|
ID is an Imaginative relaxation technique which combines physical and mental relaxation.
ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning.
Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
|
|
EXPERIMENTAL: Health professionists
Health professionists as healthy volunteers
|
ID is an Imaginative relaxation technique which combines physical and mental relaxation.
ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning.
Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
|
|
ACTIVE_COMPARATOR: Waiting list MS
pw MS filled the self administered questionnaire but they receive any training.
They must wait study conclusion to be treated
|
ID is an Imaginative relaxation technique which combines physical and mental relaxation.
ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning.
Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
|
|
ACTIVE_COMPARATOR: Waiting list arm Insomnia
pw INS Insomnia Subject filled the self administered questionnaire but they receive any training.
They must wait study conclusion to be treated
|
ID is an Imaginative relaxation technique which combines physical and mental relaxation.
ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning.
Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
|
|
ACTIVE_COMPARATOR: Waiting list arm Health professionists
Health professionist filled the self administered questionnaire but they receive any training.
They must wait study conclusion to be treated.
|
ID is an Imaginative relaxation technique which combines physical and mental relaxation.
ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning.
Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue
Time Frame: Change from baseline in MFIS score at two months + one week
|
Evaluated with MFIS self administered questionnaire.Modified Fatigue Impact Scale (MFIS) is a self-assessment,values fatigue on daily life impact.
Provides 21 items with 5-point Likert scale answer (from 0 = never to 4 = almost always).Total score ranges from 0 to 84 and includes three subscales:physical,cognitive and psychosocial fatigue (score ranges between 0-8)
|
Change from baseline in MFIS score at two months + one week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life
Time Frame: month 2;month 3;month 6
|
Includes 54 items which generate 12 subscales with two summary scores, and two additional measures given by the single item.
|
month 2;month 3;month 6
|
|
Stress
Time Frame: month 2;follow-up (month 3;month 6)
|
It consists of 15 items and breaks down into five areas of evaluation which, when added, quantify the stress response: anxiety, depression, somatization, aggression, social support
|
month 2;follow-up (month 3;month 6)
|
|
Insomnia
Time Frame: month 2
|
Consists of 7 items answered on a 4-point Likert scales, refers to the Mental Disorders Manual DSM-IV criteria for insomnia, and assesses the Individual impact of the symptoms in the last 2 weeks
|
month 2
|
|
Physiological parameters and Neurological evaluation
Time Frame: month 2,month 3;month 6
|
The EDSS is the most widely used to assess neurological disability with a score between 0 and 10
|
month 2,month 3;month 6
|
|
Cognitive screening
Time Frame: baseline,month 3
|
Symbol Digit Modalities Test.
Points 0-120.
The California Verbal Learning Test - Second Edition.
Points: 0-16 Visuospatial Memory Test - Revised.
It takes 15 minutes.
Points 0-36
|
baseline,month 3
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Multiple Sclerosis
- Sleep Initiation and Maintenance Disorders
Other Study ID Numbers
- DIMMI SI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on "Imaginative Distention" technique
-
Assaf-Harofeh Medical CenterUnknownOveractive BladderIsrael
-
Assaf-Harofeh Medical CenterCompletedAsherman SyndromeIsrael
-
Penn State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American...TerminatedIrritable Bowel SyndromeUnited States
-
Assaf-Harofeh Medical CenterUnknownInterstitial Cystitis | Painful Bladder SyndromeIsrael
-
Bergen Surgical HospitalHaukeland University Hospital; Haraldsplass Deaconess HospitalUnknownAdhesive CapsulitisNorway
-
University of BolognaRecruitingAbdominal Aortic Aneurysm | Endovascular Aortic RepairItaly
-
Universidad Autonoma de Baja CaliforniaCompletedPost Operative PainMexico
-
Escola Superior de Tecnologia da Saúde do PortoNot yet recruiting
-
Natália Maria Oliveira CampeloNot yet recruiting
-
Muş Alparlan UniversityAtaturk UniversityCompletedSatisfaction, Patient | Pain, Acute | Hematoma | Injection Fear | Injection Site BruisingTurkey